Last sum­mer we launched a prod­uct — En­ter­prise — that is es­sen­tial to the fu­ture of End­points News. Cor­po­rate cus­tomers can now di­rect­ly sup­port our fu­ture de­vel­op­ment through paid sub­scrip­tions, and get a list of ex­tra ben­e­fits and con­tent. If you’d like to sup­port the work, please con­sid­er do­ing so to­day. (We al­so have a prod­uct for in­di­vid­u­als called In­sid­er, which you can read about here.)

The news is this: We want to hit our sub­scrip­tion rev­enue goals now so we can ex­pand the team, bring­ing you even bet­ter re­port­ing soon­er rather than lat­er.  It’s just $1,000/year for your en­tire com­pa­ny no mat­ter the size — and you can see one of the ben­e­fits be­low. Every em­ploy­ee who sub­scribes to End­points News will be­gin to see this new spe­cial email head­er that demon­strates your com­pa­ny’s sup­port.

Spe­cial head­er em­ploy­ees would see with an En­ter­prise sub­scrip­tion

Get End­points En­ter­prise ($1,000/year)

This isn’t a plea for do­na­tions. With a paid sub­scrip­tion, we’re pro­vid­ing you val­ue and new tools (more on that be­low) and in ex­change we’re charg­ing a price.

To do in­de­pen­dent jour­nal­ism root­ed in the style John and I have set out since we launched — 2 years, 3,700 ar­ti­cles and 500 dai­ly newslet­ters ago — here’s one ab­solute truth: Read­ers must di­rect­ly sup­port the busi­ness mod­el. And now your com­pa­ny can.

Give your em­ploy­ees full ac­cess to end­points news

Let’s say your com­pa­ny has 2,000 em­ploy­ees. Per­haps 500 of them vis­it our web­site and 50 of them are free email sub­scribers. For just $1,000/year, you can in­stant­ly up­grade all 50 to En­ter­prise — and then as long as your sub­scrip­tion is cur­rent, we’ll au­to­mat­i­cal­ly flag all new email sub­scribers from your cor­po­rate do­main and grant them full ac­cess to your firm’s En­ter­prise li­cense.

All of your em­ploy­ees who sub­scribe to End­points News will see the spe­cial head­er in their newslet­ter, re­mind­ing them of your com­pa­ny’s sup­port of in­de­pen­dent jour­nal­ism. We’ll send them all pre­mi­um End­points con­tent which is ex­clu­sive to paid sub­scribers on­ly. And there’s more. Your em­ploy­ees al­so get:

• Print-to-PDF: The PDF but­ton above all our news ar­ti­cles will now work.
• Cut-and-paste rights: Share our work legal­ly in full, with­out the URL, in­ter­nal­ly or with part­ners, in any dig­i­tal medi­um. A huge li­brary of news con­tent at their fin­ger­tips. With­out a sub­scrip­tion, just a fair-use, lim­it­ed amount is per­mis­si­ble.
• Reprint rights: Go ahead and print our ma­te­r­i­al for busi­ness use, they’d have our full per­mis­sion.

And now:

• • Two Pre­mi­um Job List­ings: At End­points Ca­reers, we of­fer a way for cor­po­rate sub­scribers to get their open po­si­tions in front of our en­tire sub­scriber base. We’re of­fer­ing two free Pre­mi­um List­ings per year to each cor­po­rate cus­tomer. That is an $1,800 cost by it­self, which alone ex­ceeds the cost of a one year sub­scrip­tion.

Pay­wall ac­cess

Once you sub­scribe, here’s just a sam­ple of the con­tent every­one at your com­pa­ny will have ac­cess to:

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017

What you need to know about this record-set­ting biotech IPO burst as 5 more crash the par­ty look­ing for $547M

The good, the bad and the ug­ly for the top 15 spenders in the glob­al drug R&D busi­ness: 2018

Where does the sci­ence come from? The top 20 NIH-fund­ed in­sti­tu­tions in 2017

What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?

The top 20 rare dis­ease spe­cial­ists spot­light key biotech trends be­hind the boom

… and much more to come

Now is the time to sup­port the work

To the hun­dreds of amaz­ing com­pa­nies and in­di­vid­u­als who’ve al­ready signed up, thank you — what we do isn’t pos­si­ble with­out you.

If you’ve been think­ing about it but have put it off, we to­tal­ly get it. But we need your help this month if we’re to hit the lofty to­tals that’ll al­low us to hire a top-class team and build new prod­ucts while main­tain­ing our in­de­pen­dence.

Get End­points En­ter­prise

We’ve de­signed a re­al­ly easy form that takes a cou­ple min­utes to fill out, and re­quires a cred­it card pay­ment at the end. With­in 24 hours, usu­al­ly much soon­er, you’ll get an email with a full PDF li­cense. You can see the en­tire terms and con­di­tions here. All of your em­ploy­ees can start en­joy­ing the ben­e­fits of a sub­scrip­tion im­me­di­ate­ly.

Need help? Now many com­pa­nies have com­pli­cat­ed billing process­es and pro­to­cols. You can chat with our team dur­ing busi­ness hours via our up­grade page or Read­er Cen­ter should you re­quire spe­cial as­sis­tance. To sign in, you can use a tra­di­tion­al pass­word or click a se­cure “mag­ic link” that we send to your email on file with us. You can al­so send an email to help@end­pointsnews.com.

We re­quire a cred­it card pay­ment but in lim­it­ed cir­cum­stances can in­voice your com­pa­ny if there is no al­ter­na­tive.

To be­gin your com­pa­ny’s paid sub­scrip­tion, click on the but­ton be­low.

Get End­points En­ter­prise

Once again, this is a cru­cial month for this com­pa­ny. You can di­rect­ly sup­port our fu­ture de­vel­op­ment, so we can build on the track we’ve laid so far. We’ll have more posts over the month on our pro­grams but we need your sup­port to­day. Thanks for be­ing part of the End­points News com­mu­ni­ty.

A small, Santa Ana-based biotech created in 2017 is looking to enter a SPAC deal as it lays out plans to begin trials in its lead cell therapy candidates and bring on new executives.

Graf Acquisition Corp. IV and NKGen Biotech announced Thursday, with few other details, that the two companies signed a non-binding letter of intent to “pursue a business combination.” Graf Acquisition II and III withdrew their IPOs last year.

The FDA has rejected Incyte’s extended-release formulation of ruxolitinib tablets, in a surprise setback for the company’s plans to build on its blockbuster Jakafi franchise.

The ruxolitinib XR tablets are designed to be taken once a day, whereas Jakafi is indicated for twice daily dosage (although some patients can take it once daily).

According to Incyte, the FDA acknowledged in its complete response letter that the study submitted in the NDA “met its objective of bioequivalence based on area under the curve (AUC) parameters but identified additional requirements for approval.”

Cyclerion Therapeutics may have the design of a Phase IIb study ready to go, but it’s scrambling for a way to fund it.

The company said in a press release that it’s “actively evaluating the best combination of capital, capabilities, and transactions available to it to advance the development of zagociguat,” its lead candidate for a rare, genetic mitochondrial disease known as MELAS.

In a separate SEC filing, Cyclerion once again flagged “substantial doubt about (its) ability to continue as a going concern.” As of the end of 2022, it had cash and cash equivalents of only $13.4 million.